Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas

NCT01273090 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01273090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01273090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2011
Completion date
October 31, 2013
Enrollment
34 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, lymphoma, lymphoproliferative disorder, small intestine cancer, unspecified childhood solid tumor, protocol specific